Any current/future new fundraising through debt or equity?

No major new capital expenditure (capex) or large-scale investments are planned that would require significant new debt or equity fundraising. Debt is currently being managed with strict control on working capital and long-term borrowings. Debt levels have reduced by approximately INR 50 crores in the 9 months ending December 2025. From FY '29 onwards, a significant reduction in overall debt is expected due to improved cash flows and absence of major new capex. The company is financing growth initiatives through a balanced mix of internal accruals and existing debt. Current capex guidance for

Any current/future capex/capital investment/strategic investment?

FY '26 capex targeted at ~INR150 crores, down from initial guidance of INR200 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacities. INR100 crores spent in first 9 months of FY '26; additional INR40-50 crores expected in Q4 FY '26. Investment in a high-potency laboratory (Phase I) of about INR10-11 crores completed; commercial scale plant planned in FY '28. Phased repurposing of crop protection plant over next 6-18 months based on customer contracts, involving limited capex mostly for reactors and pipelines. Expansion of pilot scale capacity at Pune R&D

Future growth expectations in sales/revenue/volumes?

Pharma volumes expected to return to double-digit growth next year after minor delays in FY '26 due to FDA impact. Q3 FY '26 pharma volumes grew about 4%; strong recovery anticipated in H2 FY '26 and FY '27 onward. Crop Protection business expected to remain flattish in FY '26; pricing pressures persist but stabilization expected. New pharma products launching in FY '27 (second half) and Animal Health ramp-up by FY '28, driving growth. Animal Health targeted to be INR 500 crores+ business in 4-5 years; volumes ramping up commercially over next 2 quarters. Specialty Chemicals (Persona

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '27 is expected to mark the start of significant growth after a delayed recovery due to prior regulatory impacts; pharma segment growth will pick up strongly from early FY '27 onwards. New products, especially in pharma and animal health, have better gross margins (45-50%), leading to higher EBITDA driven by existing asset base and operating leverage. Personal Care segment and Animal Health business are poised for ramp-up in FY '27 and FY '28, contributing meaningfully to revenues and margins. Debt reduction is expected from FY '29 onwards due to improved cash flows and controlled cap

Current/ Expected Orderbook/ Pending Orders?

The order pipeline in the pharmaceutical segment is robust and growing, with a significant number of Request for Proposals (RFPs), particularly from global innovators and emerging biotech firms. Several key programs are advancing from lab to development and scale-up phases, improving medium-term revenue visibility. The Crop Protection division is seeing a quick uptick in order inflow and inquiries due to recovery in end-customer volumes, despite competitive pricing. Expansion into new geographical markets (Europe, Latin America, Middle East) is strengthening global presence and supporting orde

IN US

Sale is live|00:00:00left today

Hikal LtdQ4 FY27Pharmaceuticals & Biotechnology

Hikal Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 103.9Market Cap: ₹2.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Pharma volumes expected to return to double-digit growth next year after minor delays in FY '26 due to FDA impact.
→Q3 FY '26 pharma volumes grew about 4%; strong recovery anticipated in H2 FY '26 and FY '27 onward.
→Crop Protection business expected to remain flattish in FY '26; pricing pressures persist but stabilization expected.
→New pharma products launching in FY '27 (second half) and Animal Health ramp-up by FY '28, driving growth.
→Animal Health targeted to be INR 500 crores+ business in 4-5 years; volumes ramping up commercially over next 2 quarters.
→Specialty Chemicals (Personal Care) segment to commercialize 3-4 products in FY '27, adding a new growth lever.
→Overall growth to improve from FY '27 as remediation concludes and new product pipelines mature.
→EBITDA margins expected to improve due to better fixed cost absorption and higher-margin new products.

Margin guidance

Category 1

→FY '27 is expected to mark the start of significant growth after a delayed recovery due to prior regulatory impacts; pharma segment growth will pick up strongly from early FY '27 onwards.
→New products, especially in pharma and animal health, have better gross margins (45-50%), leading to higher EBITDA driven by existing asset base and operating leverage.
→Personal Care segment and Animal Health business are poised for ramp-up in FY '27 and FY '28, contributing meaningfully to revenues and margins.
→Debt reduction is expected from FY '29 onwards due to improved cash flows and controlled capex.
→Q3 FY '26 marked a positive turning point with operational profitability and better demand visibility; momentum expected to build through Q4 and FY '27.
→Overall, management is confident that the last 3 years of challenges will translate into sustained gains over the next 2-4 years, driving better earnings, profits, and EPS growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→No major new capital expenditure (capex) or large-scale investments are planned that would require significant new debt or equity fundraising.
→Debt is currently being managed with strict control on working capital and long-term borrowings.
→Debt levels have reduced by approximately INR 50 crores in the 9 months ending December 2025.
→From FY '29 onwards, a significant reduction in overall debt is expected due to improved cash flows and absence of major new capex.
→The company is financing growth initiatives through a balanced mix of internal accruals and existing debt.
→Current capex guidance for FY '26 is about INR 150 crores (reduced from initial INR 200 crores), showing a conservative investment approach.
→No explicit mention or indication of new equity fundraising in the near term was made during the call.

Order book

→The order pipeline in the pharmaceutical segment is robust and growing, with a significant number of Request for Proposals (RFPs), particularly from global innovators and emerging biotech firms.
→Several key programs are advancing from lab to development and scale-up phases, improving medium-term revenue visibility.
→The Crop Protection division is seeing a quick uptick in order inflow and inquiries due to recovery in end-customer volumes, despite competitive pricing.
→Expansion into new geographical markets (Europe, Latin America, Middle East) is strengthening global presence and supporting order book growth.
→New product commercializations in Personal Care and Animal Health segments are expected to add to order volume over the next 9 to 12 months.
→Repurposing of crop protection plants is aligned to customer contracts, with phased execution planned over 6 to 18 months based on confirmed orders.
→Overall, the company anticipates order inflows to resume strongly as global uncertainties ease and new capacities come online.

Capex plans

Yes

→FY '26 capex targeted at ~INR150 crores, down from initial guidance of INR200 crores, focused on debottlenecking, regulatory upgrades, and expanding CDMO capacities.
→INR100 crores spent in first 9 months of FY '26; additional INR40-50 crores expected in Q4 FY '26.
→Investment in a high-potency laboratory (Phase I) of about INR10-11 crores completed; commercial scale plant planned in FY '28.
→Phased repurposing of crop protection plant over next 6-18 months based on customer contracts, involving limited capex mostly for reactors and pipelines.
→Expansion of pilot scale capacity at Pune R&D centre underway for growing CDMO pipeline.
→Future capex post FY '26 expected to be modest with focus on adding specific lines or plants as per customer demand; major new capex unlikely.
→Capex strategy prioritizes high-ROI, targeted projects aligned with long-term growth.
→From FY '29 onwards, reduced overall debt expected as cash flows improve and capex tapers off.

How does Hikal Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Hikal Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Hikal Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio